Quantcast
Last updated on April 17, 2014 at 11:16 EDT

Latest Abiraterone Stories

2013-05-15 12:34:17

WAYNE, N.J., May 15, 2013 /PRNewswire/ -- Intended for U.S. Media Only -- Bayer HealthCare announced today that the U.S. Food and Drug Administration (FDA) approved Xofigo(®) (radium Ra 223 dichloride) for the treatment of patients with castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral metastatic disease. Xofigo is the first and only alpha particle-emitting radioactive therapeutic agent approved by the FDA that has demonstrated...

2013-05-06 12:27:10

At Six Months Post Launch, Almost One Third of Surveyed Urologists have Prescribed Xtandi in Clinical Practice, According to a New Report from BioTrends Research Group EXTON, Pa., May 6, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, at six months following launch of Xtandi (Astellas Pharma/Medivation's enzalutamide), surveyed urologists and medical oncologists prescribed...

2013-05-02 16:28:39

Conference call to be held on Thursday, May 2 at 4:30pm Eastern Time BOTHELL, Wash. and VANCOUVER, British Columbia, May 2, 2013 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today provided an overview of clinical development activities for its two product candidates, custirsen and OGX-427, and announced first quarter 2013 financial results. OGX-427 Program Update In January 2013, the Company initiated the ORCA(TM) (Ongoing Studies Evaluating Treatment Resistance...

2013-03-07 16:24:46

Conference call to be held on Thursday, March 7, 2013 at 4:30 p.m. Eastern Time BOTHELL, Wash. and VANCOUVER, British Columbia, March 7, 2013 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today highlighted key clinical development activities for its two product candidates, custirsen and OGX-427, and announced its fourth quarter and year end 2012 financial results. Custirsen Clinical Development Highlights The Company announced completion of patient enrollment of...

2013-02-12 20:21:13

ORLANDO, Fla., Feb. 12, 2013 /PRNewswire/ -- Janssen Research & Development, LLC [Janssen] announced today updated results showing ZYTIGA(®) (abiraterone acetate) plus prednisone continued to provide statistically significant improvements in disease progression compared to placebo plus prednisone, and longer overall survival in men with metastatic castration-resistant prostate cancer. The Phase 3, randomized, multicenter, placebo-controlled study (COU-AA-302) also demonstrated...

2012-12-19 12:24:32

BOTHELL, Wash. and VANCOUVER, British Columbia, Dec. 19, 2012 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today the initiation of PACIFIC, an investigator-sponsored, randomized Phase 2 study evaluating OGX-427 in men with metastatic castrate-resistant prostate cancer (CRPC) who are experiencing a rising PSA while receiving Zytiga (abiraterone acetate). The aim of the study is to determine if adding OGX-427 to Zytiga treatment can reverse or delay treatment...

2012-12-12 20:21:36

RARITAN, N.J., Dec. 12, 2012 /PRNewswire/ -- Janssen Research & Development, LLC announced today that results from analyses of COU-AA-302, a Phase 3, randomized, placebo-controlled study of ZYTIGA(® )(abiraterone acetate) plus prednisone for the treatment of metastatic castration-resistant prostate cancer (mCRPC) prior to chemotherapy, have been published online in The New England Journal of Medicine. This study was the basis of Monday's U.S. Food and Drug Administration (FDA)...

2012-12-10 16:23:22

HORSHAM, Pa., Dec. 10, 2012 /PRNewswire/ -- Janssen announced today that the U.S. Food and Drug Administration (FDA) has approved a broader indication for the oral, once-daily medication ZYTIGA(®) (abiraterone acetate). Until now, ZYTIGA with prednisone has only been approved to treat men with metastatic castration-resistant prostate cancer (mCRPC) who have received prior chemotherapy containing docetaxel. With this approval, ZYTIGA, in combination with prednisone, may now be used earlier...

2012-11-08 16:27:45

BOTHELL, Wash. and VANCOUVER, British Columbia, Nov. 8, 2012 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced third quarter 2012 financial results and highlighted key clinical development activities of its two product candidates, custirsen and OGX-427. Custirsen Clinical Development Highlights The Company announced completion of patient enrollment in the primary registration Phase 3 SYNERGY study. The SYNERGY study is designed to evaluate a survival benefit...

2012-11-06 08:29:25

BOTHELL, Wash. and VANCOUVER, British Columbia, Nov. 6, 2012 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today the completion of patient enrollment in the primary registration Phase 3 study, known as SYNERGY, evaluating custirsen in patients with advanced prostate cancer. The SYNERGY study is designed to evaluate a survival benefit for custirsen, when added to first-line chemotherapy, in men with metastatic castrate-resistant prostate cancer (mCRPC). The SYNERGY...